迈威生物：注射用7MW4911临床试验申请获FDA许可

Core Viewpoint - Maiwei (Shanghai) Biotechnology Co., Ltd. has received a Clinical Study Continuation Notification from the U.S. Food and Drug Administration (FDA), officially permitting the clinical trial application for the injectable drug 7MW4911 [1] Group 1 - The drug 7MW4911 is an innovative antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17), developed based on the company's proprietary IDDC™ antibody conjugation technology platform [1]